Canadian Multicentre Project on Standardization of PD-L1 22C3 Immunohistochemistry Laboratory Developed Tests for Pembrolizumab Therapy in Non-Small Cell Lung Cancer.

[1]  Chao Li,et al.  “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy , 2019, Modern Pathology.

[2]  Jonathan R Genzen,et al.  Regulation of Laboratory-Developed Tests , 2019, American journal of clinical pathology.

[3]  E. Valtorta,et al.  The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience , 2019, BioMed research international.

[4]  Jennifer Won,et al.  Diagnostic Accuracy in Fit-for-Purpose PD-L1 Testing , 2019, Applied immunohistochemistry & molecular morphology : AIMM.

[5]  J. Juco,et al.  Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients , 2018, Cancer cytopathology.

[6]  N. Le Stang,et al.  Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  J. T. Jørgensen,et al.  Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer. , 2018, Translational lung cancer research.

[8]  C. Copie-Bergman,et al.  Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms , 2017, PloS one.

[9]  C. Copie-Bergman,et al.  Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms , 2017, PloS one.

[10]  R. Røge,et al.  Accurate PD-L1 Protocols for Non–Small Cell Lung Cancer can be Developed for Automated Staining Platforms With Clone 22C3 , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[11]  Clive R. Taylor,et al.  Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4 Tissue Tools for Quality Assurance in Immunohistochemistry , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[12]  Jacqueline A. Hall,et al.  Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[13]  Keith Miller,et al.  Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance Characteristics. , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[14]  J. Sandbank,et al.  A Harmonization Study for the Use of 22C3 PD‐L1 Immunohistochemical Staining on Ventana’s Platform , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[16]  R. Trisolini,et al.  Fading With Time of PD-L1 Immunoreactivity in Non–Small Cells Lung Cancer Tissues: A Methodological Study , 2016, Applied immunohistochemistry & molecular morphology : AIMM.

[17]  M. Dolled-Filhart,et al.  Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer , 2016, Applied immunohistochemistry & molecular morphology : AIMM.

[18]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[19]  Mogens Vyberg,et al.  Proficiency testing in immunohistochemistry—experiences from Nordic Immunohistochemical Quality Control (NordiQC) , 2015, Virchows Archiv.

[20]  S. Nielsen.  External quality assessment for immunohistochemistry: experiences from NordiQC , 2015, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[21]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[22]  Clive R. Taylor,et al.  Standardization of Positive Controls in Diagnostic Immunohistochemistry: Recommendations From the International Ad Hoc Expert Committee , 2015, Applied immunohistochemistry & molecular morphology : AIMM.

[23]  B. Blencowe,et al.  Canadian Anaplastic Lymphoma Kinase Study: A Model for Multicenter Standardization and Optimization of ALK Testing in Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Clive R. Taylor,et al.  Standardization of Negative Controls in Diagnostic Immunohistochemistry: Recommendations From the International Ad Hoc Expert Panel , 2014, Applied immunohistochemistry & molecular morphology : AIMM.

[25]  C. Gilks,et al.  Academic and nonacademic laboratories perform equally on CIQC immunohistochemistry proficiency testing. , 2013, American journal of clinical pathology.

[26]  Clive R. Taylor,et al.  Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1 Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers , 2017, Applied immunohistochemistry & molecular morphology : AIMM.